 Aileron Therapeutics Inc NASDAQ: ALRN has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer undergoing chemotherapy. Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors. 